LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

LLY

858

+1.28%↑

UNH

565.37

+0.22%↑

NVO

131.55

+1.32%↑

JNJ

154.58

-0.46%↓

MRK

125.76

+1.19%↑

Search

AbbVie Inc

Suletud

Sektor Tervishoid

172.21 0.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

171.07

Max

173.62

Põhinäitajad

By Trading Economics

Sissetulek

547M

1.4B

Müük

-2B

12B

P/E

Sektori keskmine

42.514

79.786

Aktsiakasum

2.31

Kasumimarginaal

11.121

Töötajad

50,000

EBITDA

-2.3B

4.5B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+8.6 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

25. juuli 2024

Järgmine dividendimakse kuupäev

15. aug 2024

Järgmine aktsia dividendi kuupäev (ex-date)

10. okt 2024

Turustatistika

By TradingEconomics

Turukapital

815M

298B

Eelmine avamishind

171.48

Eelmine sulgemishind

172.21

Uudiste sentiment

By Acuity

8%

92%

5 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

AbbVie Inc Graafik

Seotud uudised

27. juuni 2024, 13:58 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Buys Celsius Therapeutics for $250 Million

26. apr 2024, 20:53 UTC

Suurimad hinnamuutused turgudel

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26. apr 2024, 12:25 UTC

Tulu

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

25. märts 2024, 13:43 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie

25. märts 2024, 13:06 UTC

Omandamised, ülevõtmised, äriostud

AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million

27. juuni 2024, 13:28 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27. juuni 2024, 13:28 UTC

Omandamised, ülevõtmised, äriostud

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27. juuni 2024, 13:26 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Acquires Celsius Therapeutics >ABBV

23. mai 2024, 20:05 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7. mai 2024, 20:30 UTC

Peamised uudised

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26. apr 2024, 13:03 UTC

Tulu

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26. apr 2024, 12:04 UTC

Tulu

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26. apr 2024, 11:41 UTC

Tulu

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

26. apr 2024, 11:40 UTC

Tulu

AbbVie Had Seen 2024 Adjusted EPS $10.97-$11.17 >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q Net $1.37B >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q U.S. HUMIRA Rev $1.77B >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q Global Skyrizi Rev $2.01B >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q Global IMBRUVICA Rev $838M >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.54B >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q International HUMIRA Rev $499M >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q EPS 77c >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q Adj EPS $2.31 >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie Sees FY Adj EPS $11.13-Adj EPS $11.33 >ABBV

26. apr 2024, 11:35 UTC

Tulu

AbbVie 1Q Rev $12.31B >ABBV

19. apr 2024, 16:43 UTC

Tulu

The Bad News Heading Into AbbVie's First-Quarter Earnings Report -- IBD

4. apr 2024, 05:00 UTC

Peamised uudised

Big Pharma Stocks Need a Rethink. Investors Keep -2-

4. apr 2024, 05:00 UTC

Peamised uudised

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake. -- Barrons.com

2. apr 2024, 12:51 UTC

Tulu

Eli Lilly's Ozempic Competitors Face Risks. Why the Stock Has More Upside. -- Barrons.com

25. märts 2024, 12:51 UTC

Omandamised, ülevõtmised, äriostud

AbbVie in Deal to Acquire Landos Biopharma for $137.5M

25. märts 2024, 12:33 UTC

Omandamised, ülevõtmised, äriostud

AbbVie: Proposed Transaction Is Expected to Close in the Second Calendar Qtr of 2024 >ABBV

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

8.6% tõus

12 kuu keskmine prognoos

Keskmine 185.85 USD  8.6%

Kõrge 200 USD

Madal 172 USD

Põhineb 15 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

12

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

169.91 / 175.27Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

5 / 369 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.